Guidolin Diego, Marcoli Manuela, Tortorella Cinzia, Maura Guido, Agnati Luigi F
Department of Neuroscience, University of Padova, Padova, Italy.
Department of Pharmacy and Center of Excellence for Biomedical Research, University of Genova, Genoa, Italy.
Front Endocrinol (Lausanne). 2019 Feb 18;10:53. doi: 10.3389/fendo.2019.00053. eCollection 2019.
The discovery of receptor-receptor interactions (RRI) has expanded our understanding of the role that G protein-coupled receptors (GPCRs) play in intercellular communication. The finding that GPCRs can operate as receptor complexes, and not only as monomers, suggests that several different incoming signals could already be integrated at the plasma membrane level via direct allosteric interactions between the protomers that form the complex. Most research in this field has focused on neuronal populations and has led to the identification of a large number of RRI. However, RRI have been seen to occur not only in neurons but also in astrocytes and, outside the central nervous system, in cells of the cardiovascular and endocrine systems and in cancer cells. Furthermore, RRI involving the formation of macromolecular complexes are not limited to GPCRs, being also observed in other families of receptors. Thus, RRI appear as a widespread phenomenon and oligomerization as a common mechanism for receptor function and regulation. The discovery of these macromolecular assemblies may well have a major impact on pharmacology. Indeed, the formation of receptor complexes significantly broadens the spectrum of mechanisms available to receptors for recognition and signaling, which may be implemented through modulation of the binding sites of the adjacent protomers and of their signal transduction features. In this context, the possible appearance of novel allosteric sites in the receptor complex structure may be of particular relevance. Thus, the existence of RRI offers the possibility of new therapeutic approaches, and novel pharmacological strategies for disease treatment have already been proposed. Several challenges, however, remain. These include the accurate characterization of the role that the receptor complexes identified so far play in pathological conditions and the development of ligands specific to given receptor complexes, in order to efficiently exploit the pharmacological properties of these complexes.
受体-受体相互作用(RRI)的发现扩展了我们对G蛋白偶联受体(GPCR)在细胞间通讯中所起作用的理解。GPCR不仅可以作为单体发挥作用,还能以受体复合物的形式运作,这一发现表明,几种不同的传入信号可能已经通过形成复合物的原聚体之间的直接变构相互作用,在质膜水平上进行整合。该领域的大多数研究都集中在神经元群体上,并已导致大量RRI的鉴定。然而,RRI不仅在神经元中出现,也出现在星形胶质细胞中,并且在中枢神经系统之外,还出现在心血管和内分泌系统的细胞以及癌细胞中。此外,涉及大分子复合物形成的RRI不仅限于GPCR,在其他受体家族中也有观察到。因此,RRI似乎是一种普遍存在的现象,而寡聚化则是受体功能和调节的常见机制。这些大分子组装体的发现很可能对药理学产生重大影响。事实上,受体复合物的形成显著拓宽了受体用于识别和信号传导的机制范围,这可以通过调节相邻原聚体的结合位点及其信号转导特性来实现。在这种情况下,受体复合物结构中可能出现的新型变构位点可能具有特别重要的意义。因此,RRI的存在为新的治疗方法提供了可能性,并且已经提出了用于疾病治疗的新型药理学策略。然而,仍然存在一些挑战。这些挑战包括准确表征目前已鉴定的受体复合物在病理条件下所起的作用,以及开发针对特定受体复合物的配体,以便有效地利用这些复合物的药理学特性。